Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 263

1.
2.

Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.

Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK.

Clin Cancer Res. 2010 Jan 15;16(2):577-86. doi: 10.1158/1078-0432.CCR-09-2015. Epub 2010 Jan 12.

3.

A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis.

Fujisawa T, Joshi B, Nakajima A, Puri RK.

Cancer Res. 2009 Nov 15;69(22):8678-85. doi: 10.1158/0008-5472.CAN-09-2100. Epub 2009 Nov 3.

4.

IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer.

Fujisawa T, Joshi BH, Puri RK.

Int J Cancer. 2012 Jul 15;131(2):344-56. doi: 10.1002/ijc.26366. Epub 2011 Sep 16.

5.

Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.

Kawakami K, Kawakami M, Joshi BH, Puri RK.

Cancer Res. 2001 Aug 15;61(16):6194-200.

6.

PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation.

Venza I, Visalli M, Fortunato C, Ruggeri M, Ratone S, Caffo M, Caruso G, Alafaci C, Tomasello F, Teti D, Venza M.

Epigenetics. 2012 Nov;7(11):1315-30. doi: 10.4161/epi.22446. Epub 2012 Oct 10.

7.

Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.

Kioi M, Seetharam S, Puri RK.

Mol Cancer Ther. 2008 Jun;7(6):1579-87. doi: 10.1158/1535-7163.MCT-07-2131.

8.

Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma.

Ye CG, Chen GG, Ho RLK, Merchant JL, He ML, Lai PBS.

Biochim Biophys Acta. 2013 Dec;1833(12):2970-2979. doi: 10.1016/j.bbamcr.2013.08.001. Epub 2013 Aug 13.

9.

Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer.

Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn CO, Heidecke CD, Friess H, Büchler M, Evert M, Lerch MM, Weiss FU.

Gut. 2012 Mar;61(3):439-48. doi: 10.1136/gutjnl-2011-300060. Epub 2011 Dec 5.

PMID:
22147512
10.

HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).

Mehdi O, Françoise S, Sofia CL, Urs G, Kevin Z, Bernard S, Igor S, Anabela CD, Dominique L, Eric M, Ali O.

Pancreatology. 2012 Mar-Apr;12(2):146-55. doi: 10.1016/j.pan.2012.02.013. Epub 2012 Feb 25.

PMID:
22487525
11.

Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine.

Fujisawa T, Nakashima H, Nakajima A, Joshi BH, Puri RK.

Int J Cancer. 2011 Mar 1;128(5):1221-31. doi: 10.1002/ijc.25437.

12.

A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.

Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC.

PLoS One. 2010 Sep 14;5(9):e12417. doi: 10.1371/journal.pone.0012417.

13.

Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.

Feng D, Wu J, Tian Y, Zhou H, Zhou Y, Hu W, Zhao W, Wei H, Ling B, Ma C.

PLoS One. 2013 Nov 19;8(11):e80657. doi: 10.1371/journal.pone.0080657. eCollection 2013.

14.

Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.

Gatla HR, Zou Y, Uddin MM, Singha B, Bu P, Vancura A, Vancurova I.

J Biol Chem. 2017 Mar 24;292(12):5043-5054. doi: 10.1074/jbc.M116.771014. Epub 2017 Feb 6.

PMID:
28167529
16.

Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.

Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK.

Cancer. 2006 Sep 15;107(6):1407-18.

17.
18.

A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.

Shieh JM, Tang YA, Hu FH, Huang WJ, Wang YJ, Jen J, Liao SY, Lu YH, Yeh YL, Wang TW, Lin P, Wang YC.

Int J Cancer. 2017 May 15;140(10):2375-2386. doi: 10.1002/ijc.30664. Epub 2017 Mar 14.

PMID:
28233309
19.

Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.

Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta SK, Urrutia RA, Sarkaria JN.

Clin Cancer Res. 2012 Aug 1;18(15):4070-9. doi: 10.1158/1078-0432.CCR-12-0560. Epub 2012 Jun 6.

20.

Supplemental Content

Support Center